Egypt's unemployment increases to 7.4% in Q1 2021: CAPMAS    Egypt's Trade Minister outlines customs clearance conditions for imported electric vehicles    Egypt raises readiness at university hospitals for Eid Al-Fitr holidays    Egypt develops Suez Canal in line with international trade movement: Al-Sisi    Egypt, Saudi Arabia, UN discuss latest developments in Jerusalem    Egypt's stocks end higher on Tuesday, benchmark EGX 30 edges up 0.77%    Abu Dhabi's Aldar looking for more deals in Egypt's real estate sector – CEO    Rid-hailing Careem, Uber raise fares after fuel hikes    Opinion| Selection bias model    Egypt's Parliament discusses abolishing imprisonment for female debtors    India to procure 300k Remdesivir doses from Egypt's Eva Pharma    Arab Observatory for Human Rights condemns Israeli violations in Jerusalem    Egypt will locally manufacture first 2m Sinovac vaccine doses by June-end    Vax Live concert exceeds vaccine goal to raise $302m    2021 South East European Film Festival celebrates cinematic diversity of 18 countries    Sheffield Documentary Film Festival announces line-up for June edition    Lebanese pop star Carole Samaha to release new album this summer    African Union chair meets Egypt's Al-Sisi within regional tour to stimulate GERD talks    We want Egypt and Sudan to agree to second filling only: Ethiopia    Turkey seeks to restore 'historic unity' with Egyptian people: Erdogan    Altibbi launches first Arabic app to support mothers' Health in Egypt among $8.5 mln investments    Al Ahly face injuries as they take on Al Ittihad Alexandria    Elneny's Arsenal targets 'remontada' in Europa League semi-finals    Zamalek eye return to victories at expense of Smouha in Egyptian Premier League    Egypt's CIB first bank in MENA, Africa to receive Gender Equity Seal    Egypt buys 30 Rafale fighter jets from France    Direct flights between Russia and Egypt will resume in June, Ambassador    Egypt's Ahly is establishing a new stadium, expected to be 'sports complex'    Blinken presses Ethiopia's Abiy to ensure full withdrawal of Eritrean troops from Tigray    Forces opposed to Somali president control parts of Mogadishu    Nine people executed in Egypt over Kerdasa police killings in 2013    UEFA investigating Ibrahimovic's alleged ties to betting company    61 doctors died from coronavirus since start of April: Egypt's medical syndicate    Egypt targets 5.6% inflation rate in FY2020/21, 6% in FY2021/22    Egypt allocates EGP 132 bln to modernise railway system: Transport minister    Real Madrid not thinking about any Super League sanctions: Zidane    Total declares force majeure on Mozambique LNG after attacks    All the winners at the 93rd Academy Awards    Egypt's Ahly granted approval to build new stadium on Cairo outskirts    Aswan Int'l Women's Film Festival dedicates 5th edition to Kawthar Heikal    BREAKING: Egypt's information minister Osama Heikal resigns amid parliamentary criticism    'War was not Egypt's aim, but peace was the ultimate goal,' Sisi says on Sinai Liberation Day anniversary    Factbox: Key nominations for the 2021 Academy Awards    Old Cairo's Al-Fustat will be revamped on Egyptian President's directives    Veteran Egyptian journalist Makram Mohamed Ahmed passes away at 86    Allianz Egypt partners with IGNITE to equip brand ambassadors for 2021 Olympics    Hassan Allam consortium wins contract to manage, operate Grand Egyptian Museum    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    

Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.

Europe scrambles as J&J vaccine delay deals another blow
Published in Ahram Online on 14 - 04 - 2021

European countries diverged Wednesday on whether they would push ahead with giving their residents Johnson & Johnson's COVID-19 vaccine after reports of very rare blood clots in a handful of recipients in the United States.
While some European Union members put the vaccine on hold as recommended by the American company, Poland, France and Hungary said they would go ahead and administer the doses that had arrived as the EU's 27 nations face continuing pressure to speed up their immunization drives.
The Johnson & Johnson vaccine, distributed in Europe by its subsidiary Janssen, is a key part of Europe's vaccination campaign, which has been criticized as sluggish. Of the four vaccines currently approved for use in the EU, J&J's is the only one that requires a single dose to be fully effective. That makes it ideal for hard-to-reach, vulnerable groups, such as those who are homeless or migrant workers.
But the drugmaker decided Tuesday to delay deliveries to Europe after the Food and Drug Administration recommended a pause in the vaccine's use in the U.S. while the rare clot cases are examined. The decision was the latest blow to the vaccine rollout in Europe, which already experienced a similar clot scare with the vaccine developed by British-Swedish company AstraZeneca.
The European Medicines Agency, the EU's regulatory agency for pharmaceutical products, has not advised EU members to put the Johnson & Johnson vaccine on hold. It said Wednesday: ``The company (J&J) is in contact with national authorities, recommending to store the doses already received until the PRAC (EMA's safety committee) issues an expedited recommendation.''
It's not clear if the exceedingly rare reports in the U.S. _ so far, six cases out of about 7 million inoculations _ are linked to the Johnson & Johnson vaccine. But European regulators already have declared that the unusual type of clots are possibly linked to the AstraZeneca vaccine, which is made with technology similar to Johnson & Johnson's product.
The AstraZeneca vaccine is in wide use around the globe, though not yet in the U.S. Several countries have imposed age restrictions on its use because of the clot concerns. Denmark, which put the vaccine on hold last month, decided Wednesday not to resume using the shots it had on hand, saying that citizens who had received a first dose would be offered a second dose of a different vaccine.
Still, experts agree COVID-19 poses a much larger risk of death and hospitalization than the potential threat of atypical clots. But the concerns could still undermine public confidence in these vaccines and in the entire vaccination effort.
On Wednesday, advisers to the U.S. Centers for Disease Control and Prevention are expected to debate how to handle the Johnson & Johnson vaccine.
The EMA, which approved the vaccine last month, said Wednesday that it will make a recommendation likely next week on how to proceed with the vaccine.
Until then, the regulator said that it ``remains of the view that the benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.''
For Poland, that meant there was no reason to wait.
``In line with these recommendations (by the EMA), we will want to use it in inoculations,'' Polish Health Minister Adam Niedzielski said.
France, which received 200,000 doses, said it is also sticking to its plan to start administering the vaccine in the middle of next week to people age 55 and over. Hungary also said it would move ahead with the doses it received. It plans to distribute them using buses that bring vaccines to rural areas.
Other countries, however, decided to hold up.
Italian Health Minister Roberto Speranza said his government was waiting for further information from the FDA and the EMA to decide how to proceed with the initial 180,000 doses that arrived in Italy Tuesday.
``But I think this vaccine must be used because it's an important vaccine, and the U.S. decision was a precautionary one, and the choice of Johnson & Johnson to not immediately put it on the market in Europe was also a precautionary choice,`` Speranza said.
``Our hope is that these knots can be resolved as soon as possible so we can use this vaccine, which would be the fourth one and is particularly useful for us,'' he said.
The Netherlands also put the 80,000 Johnson & Johnson doses it received into storage, as did Denmark, Croatia and Romania with their batches. South Africa suspended the shot as a ``precautionary measure.''
The European Union has for weeks been looking at Britain with envy as the vaccination program of its former member outpaced its own.
The J&J shot was supposed to help it play catch-up.
Under a contract with the European Commission, 200 million doses were supposed to arrive in the second quarter of this year. That deal allowed for the purchase of an additional 200 million doses.
Despite this week's delay, Spanish Prime Minister Pedro Sanchez said the EU was still on track to vaccinate 70% of adults by the end of the summer. Spain _ which received an initial shipment of 146,000 doses that are now on hold _ planned to use the shots to target groups that have been missed so far, including homeless people and migrant workers.
Austrian Chancellor Sebastian Kurz also downplayed the impact of the delay that came hours after the first doses were delivered to his country.
``I can only tell you that, with the more than 8 million doses we will have delivered by the summer . we will be able to able to offer everyone a first dose. I said at Easter within 100 days, and from today's point of view I would stick to that,'' Kurz said.
The trouble with Johnson & Johnson comes after various delays in shipments of other vaccines to Europe and the concerns with the AstraZeneca-BioNTech vaccine that first led countries to suspend its use and then impose a dizzying array of age restrictions on it.
Spain, for instance, went from using AstraZeneca on young people at first, to now only giving it people ages 60-69.
In a sign of the bloc's current thinking, European Commission President Ursula von der Leyen announced Wednesday that the bloc will start negotiating to buy 1.8 billion doses of the Pfizer-BioNTech vaccine through 2023.

Clic here to read the story from its source.